Department of Pathology and Molecular Biology, Guiyang Medical University, Guiyang, People's Republic of China.
J Alzheimers Dis. 2010;19(3):849-58. doi: 10.3233/JAD-2010-1283.
The aim of the study is to investigate the cholinergic deficit in Alzheimer's disease (AD) and identify candidate blood biomarkers for the diagnosis of the disease. Twenty-nine elderly Chinese diagnosed with AD and 33 age-matched controls were selected. The activities of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in plasma were detected by a spectrophotometric method, and the mRNA levels of alpha4 and beta2 nicotinic acetylcholine receptor (nAChR) subunits in blood leukocytes were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). The results showed that AChE activity in plasma was significantly lower in the AD group than in normal controls, while BuChE activity did not show any differences between AD and controls; mRNA levels of both alpha4 and beta2 nAChR subunits in blood leukocytes were significantly lower in the AD group than in controls. The AChE activity and the mRNA levels of alpha4 and beta2 nAChR subunits in the AD patients were also significantly correlated with cognitive test scores. No differences of AChE in plasma or alpha4 and beta2 nAChR subunits in blood leukocytes were detected between smoking and non-smoking subjects. The results indicated that the decreases in the activity of AChE and in the mRNA levels of nAChR alpha4 and beta2 subunits from the peripheral blood of patients with AD might serve as supplementary indicators for the clinical diagnosis of AD.
本研究旨在探讨阿尔茨海默病(AD)中的胆碱能缺陷,并确定用于该病诊断的候选血液生物标志物。选择 29 名被诊断为 AD 的老年中国患者和 33 名年龄匹配的对照者。采用分光光度法检测血浆中乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BuChE)的活性,通过逆转录-聚合酶链反应(RT-PCR)分析血液白细胞中α4 和β2 型烟碱型乙酰胆碱受体(nAChR)亚单位的 mRNA 水平。结果显示,AD 组血浆中 AChE 活性明显低于正常对照组,而 BuChE 活性在 AD 和对照组之间无差异;AD 组血液白细胞中α4 和β2 nAChR 亚单位的 mRNA 水平明显低于对照组。AD 患者的 AChE 活性和α4 和β2 nAChR 亚单位的 mRNA 水平与认知测试评分也显著相关。在吸烟和非吸烟患者中,血浆中 AChE 或血液白细胞中α4 和β2 nAChR 亚单位均无差异。结果表明,AD 患者外周血中 AChE 活性和 nAChR α4 和β2 亚单位的 mRNA 水平降低可能作为 AD 临床诊断的补充指标。